Alpha Emitter Market - Growth, Trends, and Forecast (2019 - 2024)

出版商 Mordor Intelligence LLP 商品編碼 353779
出版日期 內容資訊 英文 101 Pages
商品交期: 2-3個工作天內
Back to Top
全球α發射體市場:成長,趨勢,及預測(2019年∼2024年) Alpha Emitter Market - Growth, Trends, and Forecast (2019 - 2024)
出版日期: 2019年12月01日內容資訊: 英文 101 Pages




第1章 簡介

  • 調查成果
  • 調查的前提條件
  • 調查範圍

第2章 調查方法

第3章 摘要整理

第4章 市場動態

  • 市場概況
  • 成長要素
    • 標的Alpha療法潛在的優點相關意識的提高
    • 心臟病及癌症患者的增加
  • 阻礙因素
    • 放射性醫藥品的半衰期短
    • 嚴格的法律規範及償付的問題
    • 高設備投資的必要性
  • 波特的五力分析
    • 新加入廠商的威脅
    • 買主/消費者談判力
    • 供應商談判力
    • 替代產品的威脅
    • 產業內的競爭

第5章 市場區隔

  • 放射性核類別
    • 鋱(Tb-149)
    • 砈(At-211)
    • 鉍(Bi-212)
    • 錒(Ac-225)
    • 鐳(Ra-223)
    • 鉛(Pb-212)
    • 鉍(Bi -213)
  • 各醫療用途
    • 神經膠質瘤
    • 黑色素瘤
    • 胰臟癌症
    • 卵巢癌症
    • 甲狀腺
    • 骨轉移
    • 淋巴瘤
    • 內分泌腫瘤
    • 其他
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 中東、非洲
    • 南美

第6章 競爭情形

  • 企業簡介
    • Actinium Pharmaceutical Inc.
    • Alpha Tau Medical Ltd
    • Bayer AG
    • Fusion Pharmaceuticals
    • IBA Radiopharma Solutions
    • RadioMedix Inc.
    • Telix Pharmaceuticals Ltd

第7章 市場機會及今後趨勢


Product Code: 51535

Market Overview

The global alpha emitter market was valued at USD 506.5 million in 2018, and it is estimated to be valued at USD 3302.99 million by 2024 while witnessing a CAGR of 36.69% over the forecast period of 2019-2024. Certain factors that are driving the market growth include increased awareness about the potential benefits of targeted alpha therapy, and the growing number of patients with cardiac and cancer ailments.

Targeted anticancer or alpha therapy (TAT) is gaining popularity with the increasing prevalence of cancer and cardiovascular diseases. Consumers are now increasingly aware of the potential benefits of targeted therapies to cure such ailments.

Furthermore, radioimmunotherapy with short-ranged and high-efficiency α-particles is a striking and promising treatment approach. α-particles have an advantage in targeted therapy because of their exceptionally high cell-killing ability.

However, regulatory requirements pose a hurdle to translational research and clinical investigations. For instance, in the United States, all pharmacologic agents, including diagnostic radiopharmaceuticals and radiotherapeutics, undergo regulatory oversight by the FDA. Similarly, radiopharmaceuticals face additional scrutiny and undergo unique regulatory and approval pathways, across the world.

The scope of the Report

In therapeutic radiopharmaceuticals, radionuclides with alpha emitters play a significant role in treating cancers. Properties of alpha emitters have led to exert profound differences between this field and other fields of nuclear medicine. Due to their short range and high LET (deposit energy in a unit length of their pathway), alpha particles have remarkably been considered into medical research.

Key Market Trends

Medical Application in Ovarian Cancer is Expected to Observe the Highest Growth Rate over the Forecast Period

The ovarian cancer segment in the alpha emitter market is expected to witness the highest CAGR of 35.63% during the forecast period.

The growth rate is attributed to an increasing number of new diagnosis cases. As per the estimates of the American Cancer Society, in 2018, around 22,240 women were expected to receive a new diagnosis of ovarian cancer, and about 14,070 women would die from ovarian cancer.

Ovarian cancer uses radioimmunotherapy as locally injected adjuvant therapy. Trials have evaluated the practice of complete abdominal or moving-strip external-beam radiotherapy (EBRT) or non-specific i.p. radiotherapy, with colloid preparations of Au-198 or P-32 as adjuvant therapies.

Moreover, the adoption of targeted alpha therapy with higher LET and shorter wavelengths has been promising in the treatment process. This trend is expected to gain traction in the near future.

In addition, a recent Phase I clinical trial involving At-211-MX35 F (ab') showed significant efficacy, as therapeutic doses reached their targets in patients with ovarian cancer.

North America Dominates the Market and is Expected to do Same in the Forecast Period

North America currently dominates the alpha emitter market, and it is expected to continue its stronghold for a few more years. This region is expected to increase its market share in the future, owing to the fact that the increase in cardiac and neurological chronic diseases is the major driving factor for the market growth in the region. For instance, 223RaCl2 (Xofigo) is the first alpha-emitting radioisotope to gain registration in the United States for palliative therapy of prostate cancer bone metastases through indirect physiological targeting.

Moreover, according to the National Cancer Institute, the number of new cases of melanoma was 21.8 per 100,000 men and women, per year. Similarly, the rising prevalence of cancer is making it imperative for the healthcare professionals across Canada to increase the radiotherapy utilization for cancer treatment. This is directly affecting the growth of the alpha emitter market in the country.

Competitive Landscape

The global alpha emitter market is less competitive and consists of very few major players. Companies, like IBA Radiopharma Solutions, Bayer AG, Alpha Tau Medical Ltd, Actinium Pharmaceutical Inc., Telix Pharmaceuticals Ltd, RadioMedix Inc., and Fusion Pharmaceuticals hold the substantial market share in the global alpha emitter market.

A number of developments have been taking place in the market over recent years. For example, in November 2017, Actinium Pharmaceuticals launched the AWE Program, aka Actinium Warhead Enabling Program, to enable collaborations based on its Actinium-225 Technology Platform. Whereas, in November 2017, Alpha Tau Medical entered a collaboration with IRST Italy to treat its first cancer patients. This is significant progress toward international expansion. This is also expected to enable the availability of Alpha DaRT radiotherapy all across Europe, Asia, as well as the United States.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents


  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study




  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increased Awareness About the Potential Benefits of Targeted Alpha Therapy
    • 4.2.2 Increasing Number of Patients with Cardiac and Cancer Ailments
  • 4.3 Market Restraints
    • 4.3.1 Short Half-life of Radiopharmaceuticals
    • 4.3.2 Stringent Regulatory Framework and Reimbursement Issues
    • 4.3.3 Need for High Capital Investment
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry


  • 5.1 Type of Radionuclide
    • 5.1.1 Terbium (Tb-149)
    • 5.1.2 Astatine (At-211)
    • 5.1.3 Bismuth (Bi-212)
    • 5.1.4 Actinium (Ac-225)
    • 5.1.5 Radium (Ra-223)
    • 5.1.6 Lead (Pb-212)
    • 5.1.7 Bismuth (Bi -213)
  • 5.2 Medical Application
    • 5.2.1 Glioma
    • 5.2.2 Melanoma
    • 5.2.3 Pancreatic Cancer
    • 5.2.4 Ovarian Cancer
    • 5.2.5 Thyroid
    • 5.2.6 Bone Metastasis
    • 5.2.7 Lymphoma
    • 5.2.8 Endocrine Tumors
    • 5.2.9 Other Medical Applications
  • 5.3 Geography
    • 5.3.1 North America
      • United States
      • Canada
      • Mexico
    • 5.3.2 Europe
      • Germany
      • United Kingdom
      • France
      • Italy
      • Spain
      • Rest of Europe
    • 5.3.3 Asia-Pacific
      • China
      • Japan
      • India
      • Australia
      • South Korea
      • Rest of Asia-Pacific
    • 5.3.4 Middle East & Africa
      • GCC
      • South Africa
      • Rest of Middle East & Africa
    • 5.3.5 South America
      • Brazil
      • Argentina
      • Rest of South America


  • 6.1 Company Profiles
    • 6.1.1 Actinium Pharmaceutical Inc.
    • 6.1.2 Alpha Tau Medical Ltd
    • 6.1.3 Bayer AG
    • 6.1.4 Fusion Pharmaceuticals
    • 6.1.5 IBA Radiopharma Solutions
    • 6.1.6 RadioMedix Inc.
    • 6.1.7 Telix Pharmaceuticals Ltd


Back to Top